AeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical Development
Positive Phase 2a data highlight potential for once-daily dosing and sustained 24-hour bronchodilation LA JOLLA, Calif.–(BUSINESS WIRE)–AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the…